{"id":6915,"date":"2023-06-25T06:54:00","date_gmt":"2023-06-25T13:54:00","guid":{"rendered":"https:\/\/allocare.caredx.com\/?p=6915"},"modified":"2023-06-22T06:56:16","modified_gmt":"2023-06-22T13:56:16","slug":"new-antiviral-option-for-cmv-prophylaxis-after-kidney-transplant","status":"publish","type":"post","link":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2023\/06\/25\/new-antiviral-option-for-cmv-prophylaxis-after-kidney-transplant\/","title":{"rendered":"New Antiviral Option for CMV Prophylaxis After Kidney Transplant"},"content":{"rendered":"<span class=\"simplefavorite-button has-count loading\" data-postid=\"6915\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>\n<h2 class=\"wp-block-heading\"><em>\u2014 Letermovir proved noninferior to standard of care in clinical trial<\/em><\/h2>\n\n\n\n<p>By Jeff Minerd<\/p>\n\n\n\n<p>Letermovir (Prevymis) proved noninferior to valganciclovir (Valcyte), the standard of care, in a clinical trial of cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant patients, researchers reported.<\/p>\n\n\n\n<p>In a\u00a0<a rel=\"noreferrer noopener\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03443869\" target=\"_blank\">phase III trialopens in a new tab or window<\/a>\u00a0of 589 patients randomized 1:1 to receive either drug for up to 200 days post-transplant, the prevalence of CMV disease at 1 year was not significantly different in the letermovir group versus the valganciclovir group (10.4% vs 11.8%, adjusted difference -1.4%, 95% CI -6.5% to 3.8%), reported Ajit Limaye, MD, of the University of Washington Medicine in Seattle, and colleagues.<br><a href=\"https:\/\/www.medpagetoday.com\/nephrology\/kidneytransplantation\/104875\">Read the full article<\/a> in MedPage Today.<\/p>\n<span class=\"simplefavorite-button has-count loading\" data-postid=\"6915\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"0\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>","protected":false},"excerpt":{"rendered":"<p>Loading \u2014 Letermovir proved noninferior to standard of care in clinical trial By Jeff Minerd Letermovir (Prevymis) proved noninferior to valganciclovir (Valcyte), the standard of care, in a clinical trial &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2023\/06\/25\/new-antiviral-option-for-cmv-prophylaxis-after-kidney-transplant\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;New Antiviral Option for CMV Prophylaxis After Kidney Transplant&#8221;<\/span><\/a><\/p>\n","protected":false},"author":208,"featured_media":875,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":0,"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_tribe_blocks_recurrence_rules":"","_tribe_blocks_recurrence_description":"","_tribe_blocks_recurrence_exclusions":"","_ecp_custom_2":"","footnotes":""},"categories":[45,2],"tags":[2070,2069,408],"post_format":[],"Dislikes":"","Likes":"","simplefavorites_count":"","views":"1315","post_likes_plusCounter":"2","post_dislikes_plusCounter":"","acf":[],"_links":{"self":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/6915"}],"collection":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/users\/208"}],"replies":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/comments?post=6915"}],"version-history":[{"count":1,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/6915\/revisions"}],"predecessor-version":[{"id":6916,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/6915\/revisions\/6916"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media\/875"}],"wp:attachment":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media?parent=6915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/categories?post=6915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/tags?post=6915"},{"taxonomy":"post_format","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/post_format?post=6915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}